KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $514.1 million.

  • Ionis Pharmaceuticals' Non-Current Assets rose 39.99% to $514.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $514.1 million, marking a year-over-year increase of 39.99%. This contributed to the annual value of $383.4 million for FY2024, which is 10.10% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Non-Current Assets stood at $514.1 million for Q3 2025, which was up 26.01% from $408.0 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Non-Current Assets high stood at $514.1 million for Q3 2025, and its period low was $258.7 million during Q2 2021.
  • Its 3-year average for Non-Current Assets is $379.2 million, with a median of $361.7 million in 2024.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Non-Current Assets slumped by 53.62% in 2021, and later skyrocketed by 39.99% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Non-Current Assets (Quarterly) stood at $266.6 million in 2021, then grew by 24.21% to $331.2 million in 2022, then rose by 5.14% to $348.2 million in 2023, then rose by 10.10% to $383.4 million in 2024, then skyrocketed by 39.99% to $514.1 million in 2025.
  • Its Non-Current Assets stands at $514.1 million for Q3 2025, versus $408.0 million for Q2 2025 and $394.0 million for Q1 2025.